Published in J Clin Invest on March 01, 2003
ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med (2011) 3.96
Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest (2003) 2.56
Phospholamban ablation rescues sarcoplasmic reticulum Ca(2+) handling but exacerbates cardiac dysfunction in CaMKIIdelta(C) transgenic mice. Circ Res (2009) 2.12
Gene therapy in heart failure. Circ Res (2008) 1.79
Excitation-contraction coupling and mitochondrial energetics. Basic Res Cardiol (2007) 1.74
Altered intracellular Ca2+ handling in heart failure. J Clin Invest (2005) 1.70
Endoplasmic reticulum-mitochondria crosstalk in NIX-mediated murine cell death. J Clin Invest (2008) 1.65
Beta-adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev (2009) 1.40
Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest (2004) 1.33
Kinetics of cardiac muscle contraction and relaxation are linked and determined by properties of the cardiac sarcomere. Am J Physiol Heart Circ Physiol (2010) 1.31
Two close, too close: sarcoplasmic reticulum-mitochondrial crosstalk and cardiomyocyte fate. Circ Res (2010) 1.24
Temporal and mutation-specific alterations in Ca2+ homeostasis differentially determine the progression of cTnT-related cardiomyopathies in murine models. Am J Physiol Heart Circ Physiol (2009) 1.21
Pacing-induced calcineurin activation controls cardiac Ca2+ signalling and gene expression. J Physiol (2003) 1.12
Nuclear effects of G-protein receptor kinase 5 on histone deacetylase 5-regulated gene transcription in heart failure. Circ Heart Fail (2011) 1.12
Role of sarco/endoplasmic reticulum calcium content and calcium ATPase activity in the control of cell growth and proliferation. Pflugers Arch (2008) 1.08
Functional cardiac lipolysis in mice critically depends on comparative gene identification-58. J Biol Chem (2013) 1.00
Alterations in ryanodine receptors and related proteins in heart failure. Biochim Biophys Acta (2013) 0.99
Neonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol (2010) 0.97
Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes. J Mol Cell Cardiol (2010) 0.96
Ablation of phospholamban and sarcolipin results in cardiac hypertrophy and decreased cardiac contractility. Cardiovasc Res (2010) 0.94
Ca(2+) influx through L-type Ca(2+) channels and transient receptor potential channels activates pathological hypertrophy signaling. J Mol Cell Cardiol (2012) 0.94
Phospholamban knockout breaks arrhythmogenic Ca²⁺ waves and suppresses catecholaminergic polymorphic ventricular tachycardia in mice. Circ Res (2013) 0.92
Long-term rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling protein. J Mol Cell Cardiol (2011) 0.92
Return of calcium: manipulating intracellular calcium to prevent cardiac pathologies. Proc Natl Acad Sci U S A (2004) 0.91
Novel role of HAX-1 in ischemic injury protection involvement of heat shock protein 90. Circ Res (2012) 0.90
Constitutive phosphorylation of inhibitor-1 at Ser67 and Thr75 depresses calcium cycling in cardiomyocytes and leads to remodeling upon aging. Basic Res Cardiol (2012) 0.90
The challenge of molecular medicine: complexity versus Occam's razor. J Clin Invest (2003) 0.88
Induced overexpression of Na(+)/Ca(2+) exchanger does not aggravate myocardial dysfunction induced by transverse aortic constriction. J Card Fail (2013) 0.84
Gene therapy targets in heart failure: the path to translation. Clin Pharmacol Ther (2011) 0.81
Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis. J Lipid Res (2014) 0.81
Myosin binding protein C: implications for signal-transduction. J Muscle Res Cell Motil (2011) 0.79
In vitro studies of early cardiac remodeling: impact on contraction and calcium handling. Front Biosci (Schol Ed) (2011) 0.76
Palmitoyl acyltransferase Aph2 in cardiac function and the development of cardiomyopathy. Proc Natl Acad Sci U S A (2015) 0.76
A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem (1985) 90.20
The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol (1993) 8.01
Sensitivity of CaM kinase II to the frequency of Ca2+ oscillations. Science (1998) 7.29
Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res (1994) 5.01
MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell (1997) 4.67
Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A (1997) 3.89
Myosin binding protein C, a phosphorylation-dependent force regulator in muscle that controls the attachment of myosin heads by its interaction with myosin S2. Circ Res (2000) 3.32
Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell (1999) 2.68
Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science (1998) 2.64
Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice. Circulation (1998) 2.62
Cardiotrophic effects of protein kinase C epsilon: analysis by in vivo modulation of PKCepsilon translocation. Circ Res (2000) 2.38
Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med (2002) 2.37
Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol (2000) 2.25
Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation (2001) 2.22
Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways. J Biol Chem (2000) 2.12
c-Jun N-terminal kinase activation mediates downregulation of connexin43 in cardiomyocytes. Circ Res (2002) 2.11
Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med (2002) 2.05
Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J Clin Invest (1999) 2.02
Wnt-1 regulation of connexin43 in cardiac myocytes. J Clin Invest (2000) 1.87
Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice. Proc Natl Acad Sci U S A (1999) 1.85
RGS4 reduces contractile dysfunction and hypertrophic gene induction in Galpha q overexpressing mice. J Mol Cell Cardiol (2001) 1.72
Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci U S A (1998) 1.68
Cardiac intracellular calcium release channels: role in heart failure. Circ Res (2000) 1.62
Cardiac myosin binding protein C. Circ Res (1999) 1.61
Phosphorylation of troponin I controls cardiac twitch dynamics: evidence from phosphorylation site mutants expressed on a troponin I-null background in mice. Circ Res (2002) 1.56
Targeting phospholamban by gene transfer in human heart failure. Circulation (2002) 1.55
Changes in cardiac contractility related to calcium-mediated changes in phosphorylation of myosin-binding protein C. Biophys J (2001) 1.52
Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts. Circ Res (1996) 1.48
Calcium handling proteins in the failing human heart. Basic Res Cardiol (1997) 1.48
Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest (2001) 1.37
Remodeling the intercalated disc leads to cardiomyopathy in mice misexpressing cadherins in the heart. J Cell Sci (2002) 1.31
Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J Biol Chem (2000) 1.16
The enhanced contractility of the phospholamban-deficient mouse heart persists with aging. J Mol Cell Cardiol (2001) 1.13
In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy. Circ Res (1999) 1.12
MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. Proc Natl Acad Sci U S A (2002) 1.11
Epsilon protein kinase C in pathological myocardial hypertrophy. Analysis by combined transgenic expression of translocation modifiers and Galphaq. J Biol Chem (2000) 1.11
Pathogenesis of dilated cardiomyopathy: molecular, structural, and population analyses in tropomodulin-overexpressing transgenic mice. Am J Pathol (1999) 1.09
Transgenic replacement of type V adenylyl cyclase identifies a critical mechanism of beta-adrenergic receptor dysfunction in the G alpha q overexpressing mouse. FEBS Lett (1999) 1.02
Phospholamban deficiency does not compromise exercise capacity. Am J Physiol (1999) 1.02
Phospholamban deficiency alters inactivation kinetics of L-type Ca2+ channels in mouse ventricular myocytes. Am J Physiol (1997) 1.01
Expression of slow skeletal troponin I in hearts of phospholamban knockout mice alters the relaxant effect of beta-adrenergic stimulation. Circ Res (2002) 0.99
beta-Adrenergic regulation of cAMP and protein phosphorylation in phospholamban-knockout mouse hearts. Am J Physiol (1997) 0.96
Combined phospholamban ablation and SERCA1a overexpression result in a new hyperdynamic cardiac state. Cardiovasc Res (2003) 0.92
Re-evaluating sarcoplasmic reticulum function in heart failure. Nat Med (2000) 0.89
Reduction of [Ca(2+)](i) restores uncoupled beta-adrenergic signaling in isolated perfused transgenic mouse hearts. Circ Res (2001) 0.80
The enhanced contractility in phospholamban deficient mouse hearts is not associated with alterations in (Ca2+)-sensitivity or myosin ATPase-activity of the contractile proteins. Basic Res Cardiol (2000) 0.79
MicroRNA-133 controls cardiac hypertrophy. Nat Med (2007) 11.68
Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature (2005) 11.22
Truncations of titin causing dilated cardiomyopathy. N Engl J Med (2012) 6.07
Two-dimensional nanosheets produced by liquid exfoliation of layered materials. Science (2011) 6.00
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science (2007) 5.19
De novo mutations in histone-modifying genes in congenital heart disease. Nature (2013) 5.15
Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol (2003) 5.05
Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ Res (2007) 4.53
PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med (2004) 4.50
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med (2008) 3.98
De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. Nat Genet (2009) 3.86
A public resource facilitating clinical use of genomes. Proc Natl Acad Sci U S A (2012) 3.72
Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science (2003) 3.71
Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med (2005) 3.71
PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science (2013) 3.60
Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline. J Card Fail (2009) 3.54
Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med (2010) 3.42
Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med (2016) 3.40
The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet (2005) 3.36
Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest (2002) 3.33
Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation (2002) 3.20
Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res (2011) 2.99
Nix is critical to two distinct phases of mitophagy, reactive oxygen species-mediated autophagy induction and Parkin-ubiquitin-p62-mediated mitochondrial priming. J Biol Chem (2010) 2.93
Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med (2003) 2.83
Genetic causes of human heart failure. J Clin Invest (2005) 2.79
RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab (2003) 2.72
Filter-based hybridization capture of subgenomes enables resequencing and copy-number detection. Nat Methods (2009) 2.71
Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation (2009) 2.70
Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice. Circulation (2003) 2.70
Cardiac myosin-binding protein-C phosphorylation and cardiac function. Circ Res (2005) 2.67
Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest (2010) 2.64
Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest (2003) 2.56
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2011) 2.53
Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res (2005) 2.52
Cardiac myosin binding protein C phosphorylation is cardioprotective. Proc Natl Acad Sci U S A (2006) 2.46
MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res (2009) 2.40
Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis. Nat Genet (2012) 2.39
Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord (2004) 2.34
Phenotyping hypertrophy: eschew obfuscation. Circ Res (2003) 2.32
MiR-15 family regulates postnatal mitotic arrest of cardiomyocytes. Circ Res (2011) 2.32
Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation (2003) 2.28
Mitochondrial fusion is essential for organelle function and cardiac homeostasis. Circ Res (2011) 2.27
AMP-activated protein kinase in the heart: role during health and disease. Circ Res (2007) 2.27
Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet (2002) 2.27
The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest (2002) 2.26
Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice. J Clin Invest (2007) 2.23
Bimodal cardiac dysfunction in an animal model of iron overload. J Lab Clin Med (2002) 2.23
G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res (2008) 2.22
Nix-mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation. Circulation (2008) 2.21
An FHL1-containing complex within the cardiomyocyte sarcomere mediates hypertrophic biomechanical stress responses in mice. J Clin Invest (2008) 2.19
Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol (2007) 2.18
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Barcoding bias in high-throughput multiplex sequencing of miRNA. Genome Res (2011) 2.12
Phospholamban ablation rescues sarcoplasmic reticulum Ca(2+) handling but exacerbates cardiac dysfunction in CaMKIIdelta(C) transgenic mice. Circ Res (2009) 2.12
A molecular pathway including Id2, Tbx5, and Nkx2-5 required for cardiac conduction system development. Cell (2007) 2.12
Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med (2008) 2.12
Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis (2008) 2.08
Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ Res (2006) 2.08
Reduced phospholamban phosphorylation is associated with impaired relaxation in left ventricular myocytes from neuronal NO synthase-deficient mice. Circ Res (2007) 2.07
Protein kinase A phosphorylation of the ryanodine receptor does not affect calcium sparks in mouse ventricular myocytes. Circ Res (2002) 2.06
Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med (2002) 2.05
A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci U S A (2006) 2.05
Polycomb repressive complex 2 regulates normal development of the mouse heart. Circ Res (2011) 2.05
Phosphoproteome analysis of cardiomyocytes subjected to beta-adrenergic stimulation: identification and characterization of a cardiac heat shock protein p20. Circ Res (2003) 1.98
Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol (2002) 1.97
Phenotypic diversity in hypertrophic cardiomyopathy. Hum Mol Genet (2002) 1.93
Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation (2002) 1.91
Tbx5-dependent rheostatic control of cardiac gene expression and morphogenesis. Dev Biol (2006) 1.91
Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. Nat Genet (2013) 1.91